Richard Essner

Dr. Richard Essner


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MCMathew H. Chung
Mathew H. Chung
RGRishab K. Gupta
Rishab K. Gupta
EHEddy Hsueh
Eddy Hsueh
RERichard Essner
Richard Essner
YWYe Wei
Ye Wei
DMDonald L. Morton
Donald L. Morton
Purpose: A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsbad, CA) induces antibodies to a glycoprotein tumor-associated antigen (TA90). However, endogenous immune responses to TA90 have also been reported. This study examined anti-TA90 antibody responses with respect to the survival of patients who received adjuvant vaccine immunotherapy after resection of thick (≥ 4 mm) primary cutaneous melanoma.Patients and Methods: Serum specimens were obtained from 54 patients immediately before and then 1, 2, 4, and 6 months after wide local excision of thick primary cutaneous melanoma and sentinel lymphadenectomy. All patients were offered adjuvant therapies with the vaccine, high-dose interferon, or other agents. An enzyme-linked immunosorbent assay was used to determine serial serum titers of immunoglobulin G (IgG) and IgM antibodies against TA90. These titers were correlated with clinical course.Results: Forty-three patients chose vaccine therapy, and 11 patients chose postoperative observation. Preoperative anti-TA90 IgG and IgM titers were similar for vaccine and observation groups (P = .184). At a median follow-up of 26 months, univariate analysis of Cox regression showed that disease-free survival and overall survival of vaccine patients were significantly correlated with maximal IgM response (P = .0006 and .006, respectively) but not with maximal IgG response (P = .73 and .95, respectively). Neither response predicted survival in the observation group.Conclusion: Postoperative vaccine therapy may enhance IgG and IgM immune responses to TA90 after surgical resection, but only the IgM response is correlated with improved survival. These findings may become useful to guide selection of patients for postoperative adjuvant therapy of high-risk melanoma.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SASanjiv S. Agarwala
Sanjiv S. Agarwala
MRMerrick I. Ross
Merrick I. Ross
JZJonathan S Zager
Jonathan S Zager
KSKeisuke Shirai
Keisuke Shirai
RERichard Essner
Richard Essner
EWEric Andrew Wachter
Eric Andrew Wachter
9559 Background: PV-10 (rose bengal disodium) is a small molecule oncolytic immunotherapy in development for solid tumors, where intralesional injection can yield immunogenic cell death and tumor-specific reactivity in circulating T cells. It has been administered as a single agent to over 300 cutaneous melanoma patients (pts) in Phase 1-3 testing and under expanded access. Methods: Study PV-10-MM-1201 (NCT02557321) is a Phase 1b/2 study of PV-10 in combination with anti-PD-1 (pembrolizumab) for patients with advanced cutaneous melanoma (Stage IIIB-IV M1c). Patients must have at least 1 injectable lesion and be candidates for pembrolizumab. In Phase 1b pts receive combination treatment q3w for 5 cycles then pembrolizumab alone for up to 24 months; the primary endpoint is safety and tolerability with objective response rate (ORR) and progression free survival (PFS) key secondary endpoints (by RECIST 1.1 after 5 cycles then q12w). Results: Full accrual of the Main Cohort of Phase 1b was reached in April 2018, with an intent-to-treat population of 23 pts (3 IIIC/IIID, 8 M1a, 7 M1b, 5 M1c; median age 70 years, range 28-90). Treatment-Emergent Adverse Events (TEAEs) were consistent with established patterns for each drug, principally Grade 1-2 injection site reactions attributed to PV-10 and Grade 1-3 immune-mediated reactions attributed to pembrolizumab, with no significant overlap or unexpected toxicities: 6 Grade 1-2 TEAEs were attributed to the combination in 6 pts. Response of injected lesions was 77% CR (3% PR) achieved after a median of 3 injections / lesion administered over a median of 4 treatment cycles of PV-10 (range 1-5). Most pts had extensive uninjected tumor burden, and a best overall response of CR was achieved in 9% of pts (1 each M1a and M1b), with 57% of pts achieving PR (including 4 of 5 M1c pts). Response assessment is ongoing; final ORR and PFS data for the Main Cohort will be presented along with correlative T cell data. Conclusions: The primary endpoint for Phase 1b was met, with acceptable safety and tolerability of the combination and no unexpected safety issues identified. Two Phase 1b Expansion Cohorts (24 pts each) have been opened to pts refractory to prior checkpoint inhibition and pts with in-transit or satellite disease. Clinical trial information: NCT02557321.

1 January 1999 in Stereotactic and Functional Neurosurgery
Verified
Journal Article
Closed access
PDF file
JCJoseph C.T. Chen
Joseph C.T. Chen
SOSteven O’day
Steven O’day
DMDonald Morton
Donald Morton
RERichard Essner
Richard Essner
ACAron Cohen-Gadol
Aron Cohen-Gadol
MAMichael L.J. Apuzzo
Michael L.J. Apuzzo
We review 190 consecutive patients with 434 metastatic tumors treated by gamma knife stereotactic radiosurgery, from August 1994 to February 1999. Median actuarial survival for all patients was 34 weeks. Factors correlated with significantly improved survival included controlled systemic disease and nonmelanoma histology. We found that no significant survival benefit could be discerned from adjuvant whole brain radiotherapy in this patient group. Survival was not statistically different for patients initially presenting with 1–4 metastases at initial treatment.

17 November 2024 in Journal of Surgical Oncology
Verified
Journal Article
Open access
KLKristel Adeline Lourdault
Kristel Adeline Lourdault
ACArthur W. Cowman
Arthur W. Cowman
DHDouglas Hanes
Douglas Hanes
ASAnthony Scholer
Anthony Scholer
TATyler Aguilar
Tyler Aguilar
RERichard Essner
Richard Essner
Background and Objectives: Clinical nomograms have been developed to predict sentinel lymph node (SLN) status in early‐stage melanoma patients, but the clinical utility of these tools remains debatable. We created and validated a nomogram using data from a randomized clinical trial and assessed its accuracy against the well‐validated Melanoma Institute Australia (MIA) nomogram. Methods: We developed our model to predict SLN status using logistic regression on clinicopathological patient data from the Multicenter Selective Lymphadenectomy Trial‐I. The model was externally validated using the National Cancer Database (NCDB) data set, and its performance was compared to that of the MIA nomogram. Results: Our model had good discrimination between positive and negative SLNs, with a training set area under the curve (AUC) of 0.706 (0.661–0.751). Our model achieved an AUC of 0.715 (0.706–0.724) compared to 0.723 (0.715–0.731) with the MIA model, using the NCDB set. Conclusion: Our model performed similarly to the MIA model, confirming that despite using different clinical features and data sets, no clinical nomogram is currently accurate enough for clinical use.

1 July 2006 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
RSRandall P Scheri
Randall P Scheri
RERichard Essner
Richard Essner
The management of clinically normal regional lymph nodes in early-stage melanoma has been controversial for over 100 years. Lymphatic mapping and sentinel lymphadenectomy has been developed as a minimally invasive surgical technique to stage regional lymph nodes without the associated morbidity of complete lymph node dissection. Multiple retrospective studies have validated the accuracy of lymphatic mapping and sentinel lymphadenectomy and the importance of the sentinel lymph node as a prognostic tool for melanoma. Several multicenter, prospective, randomized trials are underway to validate the data of the Phase II studies and determine the therapeutic benefit of lymphatic mapping and sentinel lymphadenectomy.

1 September 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JRJamie Rand
Jamie Rand
BBBonnie L. Balzer
Bonnie L. Balzer
DFDavid P. Frishberg
David P. Frishberg
RERichard Essner
Richard Essner
WSWonwoo Shon
Wonwoo Shon